- Home
- DATS vs POAI Comparison
DATS vs POAI Comparison
Compare DATS & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- POAI
- Stock Information
- Founded
- DATS 2014
- POAI 2002
- Country
- DATS United States
- POAI United States
- Employees
- DATS N/A
- POAI N/A
- Industry
- DATS Computer Software: Prepackaged Software
- POAI Industrial Specialties
- Sector
- DATS Technology
- POAI Health Care
- Exchange
- DATS Nasdaq
- POAI Nasdaq
- Market Cap
- DATS 10.4M
- POAI 8.9M
- IPO Year
- DATS 2021
- POAI N/A
- Fundamental
- Price
- DATS $2.49
- POAI $0.88
- Analyst Decision
- DATS
- POAI Hold
- Analyst Count
- DATS 0
- POAI 1
- Target Price
- DATS N/A
- POAI N/A
- AVG Volume (30 Days)
- DATS 175.0K
- POAI 230.8K
- Earning Date
- DATS 05-15-2025
- POAI 05-15-2025
- Dividend Yield
- DATS N/A
- POAI N/A
- EPS Growth
- DATS N/A
- POAI N/A
- EPS
- DATS N/A
- POAI N/A
- Revenue
- DATS $388.00
- POAI $1,729,269.00
- Revenue This Year
- DATS N/A
- POAI $486.27
- Revenue Next Year
- DATS N/A
- POAI $65.50
- P/E Ratio
- DATS N/A
- POAI N/A
- Revenue Growth
- DATS N/A
- POAI 24.17
- 52 Week Low
- DATS $1.01
- POAI $0.55
- 52 Week High
- DATS $9.34
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- DATS 46.44
- POAI 36.28
- Support Level
- DATS $2.43
- POAI $0.87
- Resistance Level
- DATS $2.86
- POAI $0.97
- Average True Range (ATR)
- DATS 0.19
- POAI 0.08
- MACD
- DATS 0.00
- POAI -0.02
- Stochastic Oscillator
- DATS 32.73
- POAI 4.65
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.